Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial

OBJECTIVE. In the Phase 3 VELIA trial (NCT02470585), veliparib added to carboplatin plus paclitaxel concomitantly and as maintenance for women with newly-diagnosed advanced ovarian cancer significantly improved progression-free survival (PFS) versus chemotherapy alone. Here we present exploratory an...

Descripción completa

Detalles Bibliográficos
Autores principales: Aghajanian, Carol, Swisher, Elizabeth M., Okamoto, Aikou, Steffensen, Karina Dahl, Bookman, Michael A., Fleming, Gini F., Friedlander, Michael, Moore, Kathleen N., Tewari, Krishnansu S., O’Malley, David M., Chan, John K., Ratajczak, Christine, Hashiba, Hideyuki, Wu, Meijing, Dinh, Minh H., Coleman, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399938/
https://www.ncbi.nlm.nih.gov/pubmed/34930617
http://dx.doi.org/10.1016/j.ygyno.2021.12.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399938/
https://www.ncbi.nlm.nih.gov/pubmed/34930617
http://dx.doi.org/10.1016/j.ygyno.2021.12.012

Ejemplares similares